Analyst consensus rating

Oncolytics Biotech Analyst Rating: Buy

Direct answer

Oncolytics Biotech's consensus rating is Buy.

5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $4.42.
Forecast evidence checked November 17, 2026.

Get free Oncolytics Biotech email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Current price
$0.34
Average price target
$4.42
High price target
$5.82
Low price target
$2.83
Low target gap
+733.2%
Target upside
+1,200.8%
High target gap
+1,613.7%
Target range width
880.5%
Consensus rating
Buy
Analysts
5
Evidence date
November 17, 2026
Valid through
November 24, 2026

Read the frequently asked questions.

What is the analyst consensus rating for Oncolytics Biotech?

Oncolytics Biotech has a verified Buy consensus. The same dataset has an average price target of $4.42.

How far are Oncolytics Biotech's low and high targets from the recorded price?

The low target implies +733.2%, while the high target implies +1,613.7%.

How many analysts are included in Oncolytics Biotech's consensus?

The verified consensus includes 5 analysts.

How is Oncolytics Biotech's target upside or downside calculated?

The average target of $4.42 is divided by the recorded price of $0.34, then one is subtracted to produce +1,200.8%. This does not guarantee a future return.

When was Oncolytics Biotech's analyst forecast verified?

The data was verified on 2026-11-17. The dataset is valid through 2026-11-24.